MabLyte, a UK-based life science, diagnostics company, raised £150k in funding.
The backer was venture capital fund manager Mercia Fund Management (MFM), which made the investment via its Mercia Growth Fund 1.
Founded by Geoff Hale and Alice Harrison MabLyte aims to produce a range of kits for the analysis of the biological activity of monoclonal antibodies (widely used for the treatment of disease in man) and related drugs.
The company intends to use the capital to complete the development of their first kit.
FinSMEs
30/04/2013